1,721,259 research outputs found
sj-pptx-5-tam-10.1177_17588359221096878 – Supplemental material for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
No full textSupplemental material, sj-pptx-5-tam-10.1177_17588359221096878 for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia, Vincenzo Famiglietti, Erika Martinelli, Floriana Morgillo, Giulia Martini, Carminia Maria Della Corte, Davide Ciardiello, Luca Poliero, Ferdinando De Vita, Michele Orditura, Morena Fasano, Renato Franco, Michele Caraglia, Arianna Avitabile, Roberto Scalamogna, Beatrice Marchi, Fortunato Ciardiello, Teresa Troiani and Stefania Napolitano in Therapeutic Advances in Medical Oncology</p
sj-pptx-4-tam-10.1177_17588359221096878 – Supplemental material for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
No full textSupplemental material, sj-pptx-4-tam-10.1177_17588359221096878 for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia, Vincenzo Famiglietti, Erika Martinelli, Floriana Morgillo, Giulia Martini, Carminia Maria Della Corte, Davide Ciardiello, Luca Poliero, Ferdinando De Vita, Michele Orditura, Morena Fasano, Renato Franco, Michele Caraglia, Arianna Avitabile, Roberto Scalamogna, Beatrice Marchi, Fortunato Ciardiello, Teresa Troiani and Stefania Napolitano in Therapeutic Advances in Medical Oncology</p
sj-pptx-1-tam-10.1177_17588359221096878 – Supplemental material for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
No full textSupplemental material, sj-pptx-1-tam-10.1177_17588359221096878 for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia, Vincenzo Famiglietti, Erika Martinelli, Floriana Morgillo, Giulia Martini, Carminia Maria Della Corte, Davide Ciardiello, Luca Poliero, Ferdinando De Vita, Michele Orditura, Morena Fasano, Renato Franco, Michele Caraglia, Arianna Avitabile, Roberto Scalamogna, Beatrice Marchi, Fortunato Ciardiello, Teresa Troiani and Stefania Napolitano in Therapeutic Advances in Medical Oncology</p
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
No full textThe epidermal growth factor receptor (EGFR) is a cell membrane receptor that plays a key role in cancer development and progression. Ligand-activated EGFR-dependent signalling is involved in cell proliferation, apoptosis, angiogenesis and metastatic spread. Targeting the EGFR, therefore, represents a promising molecular approach in cancer treatment. Several anti-EGFR agents are in clinical development. Three drugs are currently in Phase II and III development as single agents, or in combination with other anticancer modalities: IMC-225 (cetuximab/Erbitux; ImClone), a chimaeric human-mouse monoclonal IgG(1) antibody, which blocks ligand binding and functional activation of the EGFR; OSI-774 (erlotinib/Tarceva; Genentech/OSI/Roch) and ZD1839 (gefitinib/Iressa; AstraZeneca), two small molecule EGFR-selective inhibitors of tyrosine kinase enzymatic activity, which prevent EGFR autophosphorylation and activation. Iressa is the first EGFR-targeting agent to be registered as an anticancer drug in Japan, in Australia and in the US for the third-line treatment of chemoresistant non-small cell lung cancer (NSCLC) patients. This review will focus on the preclinical background and on the results from the first series of clinical trials with these drugs. Furthermore, continuing clinical trials and a series of open clinical issues for the development of optimal strategies of using EGFR-targeting agents will be discussed
sj-pptx-2-tam-10.1177_17588359221096878 – Supplemental material for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
No full textSupplemental material, sj-pptx-2-tam-10.1177_17588359221096878 for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia, Vincenzo Famiglietti, Erika Martinelli, Floriana Morgillo, Giulia Martini, Carminia Maria Della Corte, Davide Ciardiello, Luca Poliero, Ferdinando De Vita, Michele Orditura, Morena Fasano, Renato Franco, Michele Caraglia, Arianna Avitabile, Roberto Scalamogna, Beatrice Marchi, Fortunato Ciardiello, Teresa Troiani and Stefania Napolitano in Therapeutic Advances in Medical Oncology</p
sj-pptx-3-tam-10.1177_17588359221096878 – Supplemental material for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
No full textSupplemental material, sj-pptx-3-tam-10.1177_17588359221096878 for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia, Vincenzo Famiglietti, Erika Martinelli, Floriana Morgillo, Giulia Martini, Carminia Maria Della Corte, Davide Ciardiello, Luca Poliero, Ferdinando De Vita, Michele Orditura, Morena Fasano, Renato Franco, Michele Caraglia, Arianna Avitabile, Roberto Scalamogna, Beatrice Marchi, Fortunato Ciardiello, Teresa Troiani and Stefania Napolitano in Therapeutic Advances in Medical Oncology</p
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?
No full text- …
